Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical company focused on innovative therapeutics for patients suffering from cancer and related conditions. Progenics' pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 2 testing for treatment of prostate cancer, and preclinical stage novel multiplex phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer. Progenics has exclusively licensed development and commercialization rights for its first commercial product, RELISTOR®, to Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. holds an exclusive license for the subcutaneous formulation. RELISTOR (methylnaltrexone bromide) Subcutaneous Injection is a first-in-class treatment for opioid-induced constipation approved in more than 50 countries for patients with advanced illness.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
105
Frequently Asked Questions
What is Market Cap of Progenics Pharmaceuticals, Inc.?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Progenics Pharmaceuticals, Inc. market cap is $355.05M.
What is the 52-week high for Progenics Pharmaceuticals, Inc.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Progenics Pharmaceuticals, Inc. 52 week high is $6.37 as of September 15, 2025.
What is the 52-week low for Progenics Pharmaceuticals, Inc.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Progenics Pharmaceuticals, Inc. 52 week low is $1.89 as of September 15, 2025.
What is Progenics Pharmaceuticals, Inc. stock price today?
Progenics Pharmaceuticals, Inc. stock price today is $4.10.
What was Progenics Pharmaceuticals, Inc. stock price yesterday?
Progenics Pharmaceuticals, Inc. stock price yesterday was $4.53.
What is the PE ratio of Progenics Pharmaceuticals, Inc.?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Progenics Pharmaceuticals, Inc.’s P/E ratio is None.
What is the Price-to-Book ratio of Progenics Pharmaceuticals, Inc.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Progenics Pharmaceuticals, Inc. P/B ratio is 11.5976.
What is Progenics Pharmaceuticals, Inc.'s EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Progenics Pharmaceuticals, Inc.'s EBITDA is -5.74.
What is the 50-day moving average of Progenics Pharmaceuticals, Inc.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Progenics Pharmaceuticals, Inc. 50-day moving average is $4.06.
How many employess does Progenics Pharmaceuticals, Inc. has?
Progenics Pharmaceuticals, Inc. has 105 employees.
